<?xml version='1.0' encoding='utf-8'?>
<document id="16388406"><sentence text="Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport."><entity charOffset="20-27" id="DDI-PubMed.16388406.s1.e0" text="lactone" /></sentence><sentence text="With the growing clinical usage of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), the number of reports concerning serious drug-drug interaction has been increasing" /><sentence text=" Because recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms"><entity charOffset="68-75" id="DDI-PubMed.16388406.s3.e0" text="lactone" /><entity charOffset="162-169" id="DDI-PubMed.16388406.s3.e1" text="lactone" /><pair ddi="false" e1="DDI-PubMed.16388406.s3.e0" e2="DDI-PubMed.16388406.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s3.e0" e2="DDI-PubMed.16388406.s3.e1" /></sentence><sentence text=" Thus, we investigated the inhibitory effects of acid and lactone forms of eight statins, including one recently withdrawn, cerivastatin, and two recently developed, pitavastatin and rosuvastatin, on cytochrome P450 (CYP) 2C8, CYP2C9, and CYP3A4/5 metabolic activities and multidrug resistance protein 1 (MDR1) transporting activity"><entity charOffset="58-65" id="DDI-PubMed.16388406.s4.e0" text="lactone" /><entity charOffset="124-136" id="DDI-PubMed.16388406.s4.e1" text="cerivastatin" /><entity charOffset="166-178" id="DDI-PubMed.16388406.s4.e2" text="pitavastatin" /><entity charOffset="183-195" id="DDI-PubMed.16388406.s4.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e0" e2="DDI-PubMed.16388406.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e0" e2="DDI-PubMed.16388406.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e0" e2="DDI-PubMed.16388406.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e0" e2="DDI-PubMed.16388406.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e1" e2="DDI-PubMed.16388406.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e1" e2="DDI-PubMed.16388406.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e1" e2="DDI-PubMed.16388406.s4.e3" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e2" e2="DDI-PubMed.16388406.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16388406.s4.e2" e2="DDI-PubMed.16388406.s4.e3" /></sentence><sentence text="" /><sentence text="The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells, respectively" /><sentence text="" /><sentence text="The acid forms had minimal inhibitory effects on all CYP activities tested, except for fluvastatin on CYP2C9-mediated tolbutamide 4-hydroxylation (IC50 = 1"><entity charOffset="87-98" id="DDI-PubMed.16388406.s8.e0" text="fluvastatin" /><entity charOffset="118-129" id="DDI-PubMed.16388406.s8.e1" text="tolbutamide" /><pair ddi="false" e1="DDI-PubMed.16388406.s8.e0" e2="DDI-PubMed.16388406.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s8.e0" e2="DDI-PubMed.16388406.s8.e1" /></sentence><sentence text="7 microM) and simvastatin on CYP3A4/5-mediated paclitaxel 3-hydroxylation (12"><entity charOffset="14-25" id="DDI-PubMed.16388406.s9.e0" text="simvastatin" /><entity charOffset="47-57" id="DDI-PubMed.16388406.s9.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.16388406.s9.e0" e2="DDI-PubMed.16388406.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s9.e0" e2="DDI-PubMed.16388406.s9.e1" /></sentence><sentence text="0 microM)" /><sentence text=" Lactone forms showed no or minimal inhibitory effects on CYP2C8, CYP2C9, and CYP2C19 activities, except for rosuvastatin on the CYP2C9 activity (20"><entity charOffset="1-8" id="DDI-PubMed.16388406.s11.e0" text="Lactone" /><entity charOffset="109-121" id="DDI-PubMed.16388406.s11.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.16388406.s11.e0" e2="DDI-PubMed.16388406.s11.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s11.e0" e2="DDI-PubMed.16388406.s11.e1" /></sentence><sentence text="5 microM), whereas they showed stronger inhibitory effects on the CYP3A4/5 activity with the rank order of atorvastatin (5"><entity charOffset="107-119" id="DDI-PubMed.16388406.s12.e0" text="atorvastatin" /></sentence><sentence text="6 microM), cerivastatin (8"><entity charOffset="11-23" id="DDI-PubMed.16388406.s13.e0" text="cerivastatin" /></sentence><sentence text="1 microM), fluvastatin (14"><entity charOffset="11-22" id="DDI-PubMed.16388406.s14.e0" text="fluvastatin" /></sentence><sentence text="9 microM), simvastatin (15"><entity charOffset="11-22" id="DDI-PubMed.16388406.s15.e0" text="simvastatin" /></sentence><sentence text="2 microM), rosuvastatin (20"><entity charOffset="11-23" id="DDI-PubMed.16388406.s16.e0" text="rosuvastatin" /></sentence><sentence text="7 microM), and lovastatin (24"><entity charOffset="15-25" id="DDI-PubMed.16388406.s17.e0" text="lovastatin" /></sentence><sentence text="1 microM)" /><sentence text=" Pitavastatin and pravastatin had little inhibitory effect, and a similar order was found also for testosterone 6beta-hydroxylation"><entity charOffset="1-13" id="DDI-PubMed.16388406.s19.e0" text="Pitavastatin" /><entity charOffset="18-29" id="DDI-PubMed.16388406.s19.e1" text="pravastatin" /><entity charOffset="99-111" id="DDI-PubMed.16388406.s19.e2" text="testosterone" /><pair ddi="false" e1="DDI-PubMed.16388406.s19.e0" e2="DDI-PubMed.16388406.s19.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s19.e0" e2="DDI-PubMed.16388406.s19.e1" /><pair ddi="false" e1="DDI-PubMed.16388406.s19.e0" e2="DDI-PubMed.16388406.s19.e2" /><pair ddi="false" e1="DDI-PubMed.16388406.s19.e1" e2="DDI-PubMed.16388406.s19.e1" /><pair ddi="false" e1="DDI-PubMed.16388406.s19.e1" e2="DDI-PubMed.16388406.s19.e2" /></sentence><sentence text=" MDR1-mediated transport of [3H]digoxin was inhibited only by lactone forms, and the rank order correlated with that of inhibitory effects on both CYP3A4/5 activities"><entity charOffset="28-39" id="DDI-PubMed.16388406.s20.e0" text="[3H]digoxin" /><entity charOffset="62-69" id="DDI-PubMed.16388406.s20.e1" text="lactone" /><pair ddi="false" e1="DDI-PubMed.16388406.s20.e0" e2="DDI-PubMed.16388406.s20.e0" /><pair ddi="false" e1="DDI-PubMed.16388406.s20.e0" e2="DDI-PubMed.16388406.s20.e1" /></sentence><sentence text=" Inhibitory effects on MDR1 activity, and on both CYP3A4/5 activities, could be explained by the lipophilicity; however, a significant correlation was found between the lipophilicity and inhibitory effects on CYP2C8-mediated paclitaxel 6alpha-hydroxylation" /><sentence text="" /><sentence text="We showed the difference between the acid and lactone forms in terms of drug interaction"><entity charOffset="46-53" id="DDI-PubMed.16388406.s23.e0" text="lactone" /></sentence><sentence text=" The lipophilicity could be one of the important factors for inhibitory effects" /><sentence text=" In the case of statins, it is important to examine the effects of both forms to understand the events found in clinical settings, including the pleiotropic effects" /><sentence text="" /></document>